Browse EX-10 agreements

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. REDACTED INFORMATION HAS BEEN MARKED AS “[REDACTED]”.

Form of Increase Confirmation

	To:	**The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch **as Facility Agent

From:	**CADELER A/S **as Borrower
Dated:	21 May 2026

Dear Sirs

Cadeler - Facility Agreement dated 24 November 2025 (the Facility Agreement)

…

**AEGON LTD. **

**2027 OMNIBUS INCENTIVE PLAN **

**ARTICLE I. **

**PURPOSE **

The purpose of the Aegon Ltd. 2027 Omnibus Incentive Plan (the “Plan”) is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company’s long-term performance and shareholder value by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the Plan are defined in Article XI.

**ARTICLE II. **

**ELIGIBILITY **

Service Providers are eligible to be granted Awards under the Plan, subject to the limitations described herein.

**ARTICLE III. **

**ADMINISTRATION AND DELEGATION **

…

AMENDMENT NO. 1 TO DISTRIBUTORSHIP AGREEMENT

between Taiwan Biotech Co., Ltd. and CUBEBIO Co., Ltd.

THIS AMENDMENT NO. 1 (the “Amendment”), effective as of 15th April 2026 (the “Amendment Effective Date”), is entered into between:

	(A)	Taiwan Biotech Co., Ltd., a company incorporated under the laws of Taiwan and having its office at 22, Jie-Shou Rd., Taoyuan City, Taiwan, R.O.C. and its related affiliates hereinafter collectively called (“TBC”);

…

FIRST AMENDMENT TO

DISTRIBUTORSHIP AGREEMENT

This First Amendment to Distributorship Agreement (this “Amendment”) is made and entered into as of 30th September 2025 (the “Effective Date”), by and between:

Between

Cubebio Co., Ltd.,

8F HYHILL Building, Digital-ro 10-gil 9,

Gemcheon-gu, Seoul,

Korea

(“Cubebio”)

and

Firstlink Healthcare Asia LTD.

Room B, 17/F, Loyong Court,

212-220 Lockhart Road,

wanchai, Hong Kong

(“Firstlink”)

CUBEBIO and FIRSTLINK are each a “Party” and together the “Parties.”

RECITALS

…

DISTRIBUTORSHIP AGREEMENT

**THIS AGREEMENT, **effective as of 29th of March 2024 (“Effective Date”), entered into between:

	(A)	**Taiwan Biotech Co., Ltd.., **a company incorporated under the laws of Republic of China and having its office at 22, Jie-Shou Rd., Taoyuan City, Taiwan, R.O.C. and its related affiliates hereinafter called (“TBC”)

…

Memorandum of Understanding This Memorandum of Understanding ( " MOU") is made as of 12 October 2022 by and between: (1) CUBEBIO Co . , Ltd . , a company incorporated under the laws of Republic of Korea having its office at 8 F Shinhan Life Bldg , Digital - ro 10 - gil 9 , Geumcheon - gu , Seoul Korea ; and (2) Jacobson Medical (Hong Kong) Limited, a company incorporated under the laws of Hong Kong having its office at 13 /F and 15 /F , China Trade Centre , No . 122 - 124 Wai Yip Street , Kwun Tong , Kowloon , Hong Kong The parties set out under (I) and (2) above are hereinafter collectively referred to as the "Parties " and individually as a "Party". WHEREAS the Parties intend to enter into a licence and supply agreement for certain products developed or manufactured by CUBEBIO , subject to the agreement and signing by the Parties of a detailed legally binding agreement ("Formal Agreement " ) ; The Parties have agreed as follows: - 1. Purpose . This MOU serves to confirm and memorialise both Parties' intention to commence good - faith negotiations of the provision of the Formal Agre

…

AMENDMENT AGREEMENT

t****o the Memorandum of Understanding dated 12 October 2022

This Amendment Agreement (this “Amendment”) is made as of 30 August 2024 by and between:

	(1)	CUBEBIO Co., Ltd., a company incorporated under the laws of Republic of Korea having its office at 8F HYHILL Building, Digital-ro 10-gil 9, Geumcheon-gu, Seoul, Korea; and

…

DISTRIBUTORSHIP AGREEMENT

THIS AGREEMENT, effective as of 11th of November, 2022 (“Effective Date”), entered into between:

	(A)	Firstlink Healthcare Asia Limited, a company incorporated under the laws of Hong Kong and having its office at Room B, 17/F, Loyong Court, 212-220 Lockhart Road, wanchai, Hong Kong and its related affiliates hereinafter called (“Firstlink”)

…

KO REA A D M I N I STR A TI V E SCR I VENE R S & CE R TI F IED P U B LIC TR A N S L A T O RS A SS O C I A T I O N K o r e a T r a ns l a tor s A d minist ra tive S c ri ve n e r P U BL IC T R AN S L A T O R’S F O R M P T F 1 0 1 ( R E V . 0 1 - 0 1 - 2 0 1 3 ) O f f i c e o f K o r e a A d m i n ist r a ti v e S c r i v e n e r 1 0 1 2 1 0 mm ⅹ 297 m m N u m b er o f i ss u e: 4 6 3 4 0 C E R T I F I C A TE O F T RA N SL A T I O N C o n s i g n m e n t a n d T r u s t A g re e m e nt T it l e o f D o c u m e nt ( D e s c r i p t io n o f S er vi ce) C U B E B I O C o . , L t d .: C O S M A X P H A RM A C o . , L t d. N ame o f C u st o m er I , G I C HOUL , C HO I , s ign e d b e lo w , HE R E BY C E R TI F Y th a t t h e a tt ac h e d do c um e nts we r e p r e p are d a nd t ra nsl a t e d by mys e lf a t t h e r e qu e st o f the p er son n a m e d a bove a n d th a t the t ra nsl a tion is t r ue a nd acc u r a te to the o r igin a l d o c um e nt . T he t ra nsl a t e d do c um e n t ( s) submitt e d to you ( a g e n c y) is/ a r e acc u ra t e ly a nd fa i r ly a utho r i ze d

…

** **

**[***] **

** **

Certain identified information has been excluded from this agreement, including all of the exhibits to this agreement, because it is both (i) not material and (ii) is the type of information the issuer both customarily and actually treats as private and confidential.

SERIES A INVESTMENT AGREEMENT

* *

among:

Maud Vinet

Mamato

Tristan

Meunier Triade

****(The Founders)

And:

CNRS Innovation

(The Minority Shareholders)

And:

FPCI Quantonation 1

FPCI Supernova Innovation 3

CEA Investissement

Casra Capital

(The Non-participating Existing Investors)

And:

Fonds Deep Tech 2030

FPCI Technocom 3

(The Participating Existing Investors)

* *

And: ****

** **

STMicroelectronics

ALIAD

SealSQ EIC Fund

[***]

TITANIA

(The New Investors)

In the presence of:

Quobly

(The Company)

Dated May 26, 2026

**[***] **

SERIES A INVESTMENT AGREEMENT

** **

AMONG:

** **

…

** **

The Class F shareholders

(as listed in Schedule 1 hereto)

and

WISeKey International Corp.

** **

(as the Company)

CLASS F shareholders’ agreement

Content

1	Definitions and Interpretation	1
** **	** **	** **
2	Class F Shares Voting Agreement	3
** **	** **	** **
3	Constitutional Documents	3
** **	** **	** **
4	Accession Deeds	3
** **	** **	** **

…

---

Exhibit 10.8

FRAMEWORK AGREEMENT

between

National Agency for New Technologies, Energy and Sustainable Economic Development

(ENEA)

and

NEWCLEO S.R.L.

This framework agreement (hereinafter the “FA”) is made between:

the Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA), having its registered office at Lungotevere G.A. Thaon di Revel, 76, 00196 Rome (Italy), hereby represented by the President Mr. Gilberto Dialuce, and hereinafter referred to as “ENEA”

and

Newcleo S.r.l., a company organized and existing under the law of Italy and having its registered office at Via Galliano 27, 10129 Turin (TO), Italy, registered at Turin Companies Register under number 12517780016, hereby represented by Ms. Elisabeth Rizzotti as sole Director, hereinafter referred to as “NEWCLEO”,

each, individually, a “Party” and, collectively, the “Parties”:

WHEREAS:

…